Kuluöztürk M - Search Results

1

Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia.

Kuluöztürk M, İn E, Telo S, Karabulut E, Geçkil AA. Kuluöztürk M, et al. J Med Virol. 2021 May;93(5):3113-3121. doi: 10.1002/jmv.26870. Epub 2021 Feb 17. J Med Virol. 2021. PMID: 33570194 Free PMC article.

2

Can copeptin predict the severity of coronavirus disease 2019 infection?

İn E, Kuluöztürk M, Telo S, Toraman ZA, Karabulut E. İn E, et al. Among authors: kuluozturk m. Rev Assoc Med Bras (1992). 2021 Aug;67(8):1137-1142. doi: 10.1590/1806-9282.20210525. Rev Assoc Med Bras (1992). 2021. PMID: 34669859 Free article.

3

Using artificial intelligence to improve the diagnostic efficiency of pulmonologists in differentiating COVID-19 pneumonia from community-acquired pneumonia.

İn E, Geçkil AA, Kavuran G, Şahin M, Berber NK, Kuluöztürk M. İn E, et al. Among authors: kuluozturk m. J Med Virol. 2022 Aug;94(8):3698-3705. doi: 10.1002/jmv.27777. Epub 2022 May 2. J Med Virol. 2022. PMID: 35419818 Free PMC article.

4

Serum Cystatin C Levels in COPD: Potential Diagnostic Value and Relation between Respiratory Functions.

Telo S, Kuluöztürk M, Deveci F, Kırkıl G, Öner Ö, Kaman D. Telo S, et al. Among authors: kuluozturk m. J Med Biochem. 2018 Dec 1;37(4):434-440. doi: 10.1515/jomb-2017-0064. eCollection 2018 Dec. J Med Biochem. 2018. PMID: 30584402 Free PMC article.

5

The relationship between platelet-to-lymphocyte ratio and pulmonary embolism severity in acute pulmonary embolism.

Telo S, Kuluöztürk M, Deveci F, Kirkil G. Telo S, et al. Among authors: kuluozturk m. Int Angiol. 2019 Feb;38(1):4-9. doi: 10.23736/S0392-9590.18.04028-2. Epub 2019 Jan 4. Int Angiol. 2019. PMID: 30618227 Free article.

6

Prognostic value of copeptin in patients with acute pulmonary thromboembolism.

Deveci F, Öner Ö, Telo S, Kırkıl G, Balin M, Kuluöztürk M. Deveci F, et al. Among authors: kuluozturk m. Clin Respir J. 2019 Oct;13(10):630-636. doi: 10.1111/crj.13071. Epub 2019 Aug 16. Clin Respir J. 2019. PMID: 31356733

7

Endocan as a marker of disease severity in pulmonary thromboembolism.

Kuluöztürk M, İn E, İlhan N. Kuluöztürk M, et al. Clin Respir J. 2019 Dec;13(12):773-780. doi: 10.1111/crj.13089. Epub 2019 Oct 7. Clin Respir J. 2019. PMID: 31556240

8

MR-proADM and MR-proANP levels in patients with acute pulmonary embolism.

Öner Ö, Deveci F, Telo S, Kuluöztürk M, Balin M. Öner Ö, et al. Among authors: kuluozturk m. J Med Biochem. 2020 Sep 2;39(3):328-335. doi: 10.2478/jomb-2019-0049. J Med Biochem. 2020. PMID: 33269021 Free PMC article.

9

Endocan as a potential biomarker of disease severity and exacerbations in COPD.

İn E, Kuluöztürk M, Turgut T, Altıntop Geçkil A, İlhan N. İn E, et al. Among authors: kuluozturk m. Clin Respir J. 2021 Apr;15(4):445-453. doi: 10.1111/crj.13320. Epub 2020 Dec 28. Clin Respir J. 2021. PMID: 33319462

10

The effect of radiological distribution on the COVID-19 disease.

Kuluöztürk M, İn E, Turgut T, Aydın AM, Aşçı Toraman Z, Deveci F. Kuluöztürk M, et al. Tuberk Toraks. 2021 Jun;69(2):187-195. doi: 10.5578/tt.20219808. Tuberk Toraks. 2021. PMID: 34256509 Free article. English.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters